Neuraceq[®] (florbetaben F18 injection) Scan Report

Patient Name:		Gender:	Date of Study:
Date of birth:	Age:	Medical Record #:	
Ordering Physician:			
Reason for Procedure:			
PET IMAGING PROTOCOL:			
Dose (Neuraceq): (mC	ci)		
Time of injection:			
Saline flush: (m)		
Time of scan:			
Type of acquisition (2D/3D):	D	(5	(
Static: (min) O l	x Dynamic:	(Frames) x	_ (min)
Reconstruction method (e.g. FBP/O Matrix size: Attenuation Correction: Other corrections: Sca	CT 🗆 MRI 🗆	Other	_
IMAGING FINDINGS:			
Temporal lobes:			
Frontal lobes:			
Precuneus and cingulate region:			
Parietal lobes:			
Other findings:			
FINAL IMPRESSION:			
Date of Final Report:			
Interpreting Physician:			
·····			

Neuraceq is a radioactive diagnostic agent indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β -amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's Disease (AD) and other causes of cognitive decline. A negative Neuraceq scan indicates sparse to no neuritic plaques and is inconsistent with a neuropathological diagnosis of AD at the time of image acquisition; a negative scan result reduces the likelihood that a patient's cognitive impairment is due to AD. A positive Neuraceq scan indicates moderate to frequent amyloid neuritic plaques; neuropathological examination has shown this amount of amyloid neuritic plaque is present in patients with AD, but may also be present in patients with other types of neurologic conditions as well as older people with normal cognition. Neuraceq is an adjunct to other diagnostic evaluations.

Limitations of Use

- A positive Neuraceq scan does not establish the diagnosis of AD or any other cognitive disorder.
- Safety and effectiveness of Neuraceq have not been established for:
 - Predicting development of dementia or other neurologic conditions
 - o Monitoring responses to therapies